ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 38

Angiopoietin-like 4 Is over-Expressed in Rheumatoid Arthritis: A Potential Role in Pathological Bone Resorption

Catherine Swales1, Nick Athanasou2 and Helen Knowles3, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, The Botnar Research Centre, Oxford, United Kingdom, 2Nuffield Orthopaedic Centre, Department of Pathology, Oxford, United Kingdom, 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: osteoclasts, rheumatoid arthritis (RA) and synovium

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling

Session Type: Abstract Submissions (ACR)

Background/Purpose

In contrast to normal synovial tissue, rheumatoid synovium is hypoxic, and expresses the hypoxia-inducible transcription factors HIF-1α and HIF-2α which allow the transcription of genes involved in angiogenesis, inflammation, apoptosis and regulation of immune function. Hypoxia also stimulates osteoclast differentiation and causes a HIF-1α-dependent 3-fold increase in bone resorption. Angiopoietin-like 4 (ANGPTL4) is a hypoxia- and HIF-inducible pro-angiogenic adipokine that is induced in fibroblast-like synoviocytes in rheumatoid arthritis. This study sought to investigate whether ANGPTL4 is expressed in osteoclasts and other cells within rheumatoid synovial tissue, and to compare serum and synovial fluid levels of ANGPTL4 with those in normal controls and patients with osteoarthritis.

Methods

Serum, synovial fluid and synovial tissue samples were derived from patients with osteoarthritis (OA) and rheumatoid arthritis (RA); serum was obtained from aged-matched normal controls. All donors were recruited from the Nuffield Orthopaedic Centre, Oxford, UK and gave written informed consent. ANGPTL4 and HIF-1α expression was assessed in OA and RA synovial sections by immunohistochemistry and immunofluorescence. Serum and synovial fluid levels of ANGPTL4 were measured by ELISA. Osteoclasts were differentiated from circulating RA monocytes using M-CSF and RANKL, and hypoxic induction of ANGPTL4 mRNA was measured by real-time PCR.

Results

Bone-apposing osteoclasts within the rheumatoid synovium expressed ANGPTL4 and its regulating transcription factor HIF-1α. ANGPTL4 was strongly expressed in synovial lining cells, endothelial cells, stromal cells, CD68+ macrophages and plasma cells within the RA synovium. Little ANGPTL4 was evident in normal synovium, mirroring the expression pattern of HIF-1α in rheumatoid versus normal synovial tissue. ANGPTL4 concentrations were higher in the serum and synovial fluid of RA patients than in OA patients or normal controls. High serum ANGPTL4 correlated with elevated levels of the serum bone resorption marker sRANKL. Finally, ANGPTL4 mRNA was induced 5.5-fold by hypoxia in monocyte-derived osteoclasts from RA patients. 

Conclusion

ANGPTL4 is over-expressed in both the serum and the synovial fluid and tissue of RA patients. Expression of ANGPTL4 in bone-apposing osteoclasts and correlation of high serum ANGPTL4 with circulating sRANKL suggests ANGPTL4 as a marker for bone destruction, and a potential target for inhibition of osteoclast-mediated bone resorption in RA.


Disclosure:

C. Swales,
None;

N. Athanasou,
None;

H. Knowles,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/angiopoietin-like-4-is-over-expressed-in-rheumatoid-arthritis-a-potential-role-in-pathological-bone-resorption/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology